117 related articles for article (PubMed ID: 22576194)
1. The science of biosimilars.
Bourzac K
Cancer Discov; 2012 Apr; 2(4):295. PubMed ID: 22576194
[No Abstract] [Full Text] [Related]
2. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
3. Biosimilars take center stage.
Adams KT
Manag Care; 2014 Apr; 23(4):44-6. PubMed ID: 24864533
[No Abstract] [Full Text] [Related]
4. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in rheumatology: perspective and concerns.
Scheinberg MA; Azevedo VF
Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
[No Abstract] [Full Text] [Related]
6. Introduction and commentary: Biosimilars-clinical trial and safety considerations.
Reinisch W
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S1. PubMed ID: 26058548
[No Abstract] [Full Text] [Related]
7. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab.
Ebbers HC; van Meer PJ; Moors EH; Mantel-Teeuwisse AK; Leufkens HG; Schellekens H
Drug Discov Today; 2013 Sep; 18(17-18):872-9. PubMed ID: 23688584
[TBL] [Abstract][Full Text] [Related]
8. [Biosimilars: assessment of efficacy, safety and cost].
Domínguez-Gil Hurlé A
Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars in IBD: hope or expectation?
Gecse KB; Khanna R; van den Brink GR; Ponsioen CY; Löwenberg M; Jairath V; Travis SP; Sandborn WJ; Feagan BG; D'Haens GR
Gut; 2013 Jun; 62(6):803-7. PubMed ID: 23503043
[No Abstract] [Full Text] [Related]
10. The benefits and drawbacks of biosimilars.
Cronstein BN
Clin Adv Hematol Oncol; 2015 Oct; 13(10):639-41. PubMed ID: 27058566
[No Abstract] [Full Text] [Related]
11. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
[No Abstract] [Full Text] [Related]
12. A survey among hospital specialists and pharmacists about biosimilars.
Pasina L; Casadei G; Nobili A
Eur J Intern Med; 2016 Nov; 35():e31-e33. PubMed ID: 27461988
[No Abstract] [Full Text] [Related]
13. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
14. Japanese regulatory authority's perspective on biosimilars.
Nagai S; Yanagihara R; Kishioka Y
Lancet Oncol; 2015 Mar; 16(3):e101. PubMed ID: 25752552
[No Abstract] [Full Text] [Related]
15. Japanese regulatory authority's perspective on biosimilars - authors' reply.
Bennett CL; Chen B; Hermanson T; Georgantopoulos P; Sartor OA
Lancet Oncol; 2015 Mar; 16(3):e102. PubMed ID: 25752553
[No Abstract] [Full Text] [Related]
16. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
17. Effective pharmaceutical regulation needs alignment with doctors.
Ebbers HC; Pieters T; Leufkens HG; Schellekens H
Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
[TBL] [Abstract][Full Text] [Related]
18. A consistency approach for evaluation of biosimilar products.
Tsou HH; Chang WJ; Hwang WS; Lai YH
J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars in rheumatology: the wind of change.
Schneider CK
Ann Rheum Dis; 2013 Mar; 72(3):315-8. PubMed ID: 23390018
[No Abstract] [Full Text] [Related]
20. How biosimilars will impact costs and care in oncology.
Lyman GH
Clin Adv Hematol Oncol; 2019 Oct; 17(10):544-547. PubMed ID: 31730579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
